English 
Japanese 
TOKYO, Japan, 5th Jan. 2022: — PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multitarget research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Read Full Press Release
Archives: News
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) / β-catenin inhibitor E7386, a medium-molecular weight compound created through collaboration research between Eisai and PRISM, has achieved the clinical POC (Proof of Concept). Read Full Press Release
PRISM BioLab raised 100 million yen in Series C funding from Eisai
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...
The paper of peptidomimetics is published in ACS Omega
This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Takashima, Hajime; Yoshimori, Atsushi; Honda, Eiji; Taguri, Tomonori; Ozawa, Jun; Kasai, Masaji; Shuto,
Satoshi; Takehara, Dai
PRISM BioLab raised 1.3 billion yen in Series C funding
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release
Generalized-ensemble method study: A helix-mimetic compound inhibits protein-protein interaction by long-range and short-range intermolecular interactions
Journal of Computational Chemistry, 42(14), 956-969 (2021)
Higo, Junichi; Takashima, Hajime; Fukunishi, Yoshifumi; Yoshimori, Atsushi
E7386, a selective inhibitor of the interaction between β-catenin and CBP, exerts antitumor activity in tumor models with activated canonical wnt signaling
Cancer Research, 81(4), 1052-1062 (2021)
Yamada, Kazuhiko; Hori, Yusaku; Inoue, Satoshi; Yamamoto, Yuji; Iso, Kentaro; Kamiyama, Hiroshi; Yamaguchi, Atsumi; Kimura, Takayuki; Uesugi, Mai; Ito, Junichi; Matsuki, Masahiro; Nakamoto, Kazutaka; Harada, Hitoshi; Yoneda, Naoki; Takemura, Atsushi; Kushida, Ikuo; Wakayama, Naomi; Kubara, Kenji; Kato, Yu; Semba, Taro; Yokoi, Akira; Matsukura, Masayuki; Odagami, Takenao; Iwata, Masao; Tsuruoka, Akihiko; Uenaka, Toshimitsu; Matsui, Junji; Matsushima, Tomohiro; Nomoto, Kenichi; Kouji, Hiroyuki; Owa, Takashi; Funahashi, Yasuhiro; Ozawa, Yoichi
Anti-tumor activity of the small molecule inhibitor PRI-724 against β-catenin-activated hepatocellular carcinoma
Anticancer Research, 40, 5211-5219 (2020)
Gabata, Ryosuke; Harada, Kenichi; Mizutani, Yuki; Ouchi, Hirofumi; Yoshimura, Kaori; Sato, Yasunori; Kitao, Azusa; Kimura, Kiminori; Kouji, Hiroyuki; Miyashita, Tomoharu; Tajima, Hidehiro; Ohta, Tetsuo
β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis
Scientific Reports, 9(1), 20056 (2019)
Hirakawa, Tomoko; Nasu, Kaei; Miyabe, Saori; Kouji, Hiroyuki; Katoh, Akira; Uemura, Naoto; Narahara, Hisashi